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Long-term usage of rosiglitazone, a synthetic PPARg
agonist, increases fracture rates among diabetic
patients. PPARg suppresses osteoblastogenesis
while activating osteoclastogenesis, suggesting that
rosiglitazone decreases bone formation while sus-
taining or increasing bone resorption. Using mouse
models with genetically altered PPARg, PGC1b, or
ERRa, here we show that PGC1b is required for
the resorption-enhancing effects of rosiglitazone.
PPARg activation indirectly induces PGC1b expres-
sion by downregulating b-catenin and derepressing
c-jun. PGC1b, in turn, functions as a PPARg coacti-
vator to stimulate osteoclast differentiation. Com-
plementarily, PPARg also induces ERRa expression,
which coordinates with PGC1b to enhance mito-
chondrial biogenesis and osteoclast function. ERRa
knockout mice exhibit osteoclast defects, revealing
ERRa as an important regulator of osteoclastogene-
sis. Strikingly, PGC1b deletion in osteoclasts con-
fers complete resistance to rosiglitazone-induced
bone loss. These findings identify PGC1b as an
essential mediator for the PPARg stimulation of
osteoclastogenesis by targeting both PPARg itself
and ERRa, thus activating two distinct transcrip-
tional programs.
INTRODUCTION
Bone is a dynamic tissue that constantly remodels by balancing
osteoclast-mediated bone resorption and osteoblast-mediated
bone formation. Osteoclasts are derived from hematopoietic
progenitors (Ash et al., 1980) in the monocyte/macrophage
lineage (Scheven et al., 1986; Tondravi et al., 1997) and differen-
tiate in response to the tumor necrosis factor family cytokine
receptor activator of NFkB ligand (RANKL) (Lacey et al., 1998;
Yasuda et al., 1998); in contrast, osteoblasts are of mesen-
chymal lineage (Pittenger et al., 1999). Bone homeostasis is nor-
mally maintained by the tight coupling of bone resorption and
bone formation (Edwards and Mundy, 2008). Pathological
increases in osteoclast activity and bone resorption, thus the
uncoupling of bone remodeling, can cause several diseases,Cincluding osteoporosis, arthritis, and bonemetastasis of cancers
(Novack and Teitelbaum, 2008).
Peroxisome proliferator-activated receptor g (PPARg) is a
member of the nuclear receptor family of transcription factors
that can be activated by lipophilic ligands (Evans et al., 2004;
Tontonoz and Spiegelman, 2008). It regulates a diverse spec-
trum of physiological processes, including adipogenesis (Tonto-
noz et al., 1994), lipid metabolism (Chawla et al., 2001; Tontonoz
et al., 1998), insulin sensitivity (Agostini et al., 2006; Barroso
et al., 1999; He et al., 2003), and inflammation (Jiang et al.,
1998; Ricote et al., 1998; Wan et al., 2007b), as well as diseases
such as diabetes, obesity, and atherosclerosis (Evans et al.,
2004; Lehrke and Lazar, 2005; Tontonoz and Spiegelman, 2008).
Its importance is accentuated by the widespread use of thiazo-
lidinediones (TZDs), synthetic PPARg ligands, as drugs for
insulin resistance and type 2 diabetes, including Avandia (rosigli-
tazone or BRL 49653) and Actos (pioglitazone) (Lehmann
et al., 1995; Nolan et al., 1994; Tontonoz and Spiegelman,
2008). Epidemiological studies suggest that skeletal fragility is
increased in type 2 diabetes mellitus (Grey, 2009; Strotmeyer
and Cauley, 2007). Recent clinical trials report that long-term
use of rosiglitazone increased fracture rates among diabetic
patients (Grey, 2009; Home et al., 2009; Kahn et al., 2006, 2008).
Thus, TZD administration exacerbates skeletal fragility in a
population already at increased fracture risk, and it is of para-
mount importance and urgency to elucidate the cellular and
molecular mechanisms by which PPARg and TZDs regulate
bone remodeling. Moreover, TZD treatment causes bone loss
in mice and rats, indicating that these animal models represent
relevant experimental systems to dissect TZD actions in bone
(Ali et al., 2005; Lazarenko et al., 2007; Li et al., 2006; Sottile
et al., 2004).
Emerging evidence suggests that PPARg plays important
roles in skeletal homeostasis. PPARg suppresses osteoblast
differentiation from mesenchymal stem cells (Akune et al.,
2004; Barak et al., 1999; Cock et al., 2004; Kubota et al., 1999;
Rosen et al., 1999). Our recent study reveals that PPARg also
promotes osteoclast differentiation from hematopoietic stem
cells (Wan et al., 2007a). Loss of PPARg function in mouse
hematopoietic lineages causes osteoclast defects manifested
as osteopetrosis, a disease characterized by increased bone
mass and extramedullary hematopoiesis in the spleen. Gain of
PPARg function by rosiglitazone (BRL) activation enhances
osteoclastogenesis and bone resorption in vitro and in vivo.
Thus, TZDs increase skeletal fragility by inhibiting bone forma-
tion while sustaining or increasing bone resorption, leading toell Metabolism 11, 503–516, June 9, 2010 ª2010 Elsevier Inc. 503
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Figure 1. PPARg Activation Induces PGC1b Transcription during Osteoclast Differentiation
(A) RNA expression of PGC1bwas induced during a 72 hr time course of RANKL treatment andwas further stimulated by BRL. Bonemarrow cells from gf/f control
mice (cre) or gf/fTie2cre mutant mice (+cre) were cultured with MCSF for 3 days in the presence of BRL or vehicle. On day 4 (0 hr), the macrophage precursors
were differentiated with RANKL and MCSF for 3 days (72 hr) in the presence of BRL or vehicle. ‘‘Veh’’ indicates RANKL alone; ‘‘BRL’’ indicates RANKL+BRL.
The p values were calculated by comparing each time point with 0 hr baseline control; n = 3.
(B) The BRL induction of PGC1b preceded the BRL induction of osteoclast marker genes.
Cell Metabolism
PGC1b Is Required for TZD-Induced Bone Loss
504 Cell Metabolism 11, 503–516, June 9, 2010 ª2010 Elsevier Inc.
Cell Metabolism
PGC1b Is Required for TZD-Induced Bone Lossthe uncoupling of bone remodeling and a net loss of bone
(Lazarenko et al., 2007; Wahli, 2008; Wan et al., 2007a). A recent
clinical study examining bone biomarkers in participants ran-
domized to rosiglitazone in a diabetes outcome progression trial
(ADOPT) demonstrated that bone resorption was significantly
increased in women taking rosiglitazone (Zinman et al., 2009).
In this study, we aim to determine the molecular mechanisms
by which PPARg stimulates osteoclastogenesis.
PPARg modulates transcription through ligand-mediated
recruitment of coactivators. Tissue-specific differences in coac-
tivator expression can affect PPARg function, adding another
dimension to the complexity of its gene- and cell-specific tran-
scriptional regulation (Yu and Reddy, 2007). To determine the
PPARg coactivator in osteoclasts, we measured the expression
of several nuclear receptor coactivators and found that PGC1b
(peroxisome proliferator-activated receptor-gamma coactivator
1b, Ppargc1b) is highly upregulated during osteoclast differenti-
ation. Thus, we hypothesize that PGC1b may be involved in
PPARg regulation of osteoclastogenesis. PGC1b is a transcrip-
tional coactivator that regulates energy metabolism by stimu-
lating mitochondrial biogenesis and respiration of cells (Kamei
et al., 2003; Lai et al., 2008; Lelliott et al., 2006; Lin et al., 2005;
Sonoda et al., 2007b; Vianna et al., 2006). Intriguingly, a recent
study reported that PGC1b deletion causes defects in both
osteoclasts and osteoblasts. PGC1b was induced during osteo-
clast differentiation by reactive oxygen species. Knockdown of
PGC1b in vitro inhibited osteoclast differentiation and mitochon-
dria biogenesis, and global PGC1b deletion in mice resulted in
increased bone mass. However, the mechanisms underlying
PGC1b regulation of osteoclasts were underexplored. In addi-
tion, defects were also observed in PGC1b-deficient osteoblasts
(Ishii et al., 2009); thus, it was unclear whether PGC1b deletion in
osteoclasts was sufficient to cause a resorption defect. Here,
we report that PGC1b is highly induced by BRL during osteo-
clast differentiation in a PPARg-dependent manner. Moreover,
PGC1b is required for the pro-osteoclastogenic effect of BRL
in vivo and ex vivo. PGC1b functions as a PPARg coactivator
to stimulate osteoclast differentiation. Complementarily, PGC1b
also coordinates with the BRL-induced ERRa to enhance mito-
chondrial biogenesis and osteoclast function. Importantly, using
conditional PGC1b knockout mice, we have investigated the
specific requirement for osteoclastic PGC1b in rosiglitazone-
induced bone loss.(C) Western blot analysis showed that PGC1b protein level was induced by RANK
entiation culture after 72 hr.
(D) Transient transfection assays showed that the PGC1b promoter was induced b
indicated transcription factor or were alternatively treated with RANKL overnight, 2
fected; thus, half c-jun was transfected in ‘‘0.5 jun 0.5 fos’’ compared to ‘‘jun.’’ T
fected and untreated control (left); n = 3. g, PPARg; a, RXRa; vec, vector.
(E) Alignment of mouse, rat, and human PGC1b-A and PGC1b-B AP-1-binding r
(F) ChIP analysis of c-jun binding to the endogenousmouse PGC1b-A and PGC1b
and RANKL treatment; n = 3.
(G) Both basal expression and c-jun induction of PGC1b promoter were significan
b-catenin mutant (bCA) was cotransfected; n = 3.
(H) Western blot analysis of bone marrow differentiation culture showed that the
by BRL.
(I) b-catenin deletion or c-jun overexpression induced PGC1b expression. Macrop
virally transduced with cre, c-jun, or vector control. PGC1b mRNA expression w
Error bars in (A), (B), (D), (F), (G), and (I) represent means ± SD.
CRESULTS
PPARg Activation Induces PGC1b Expression
during Osteoclast Differentiation
In our previous study, we generated the PPARgflox/flox; Tie2cre+/
(gf/fTie2cre) mice in which PPARg was deleted in hematopoietic
lineages, but not in mesenchymal lineages; thus, in osteoclasts,
but not in osteoblasts (Wan et al., 2007a). We isolated bone
marrow cells from gf/fTie2cre (+cre) mutants or gf/f (cre) con-
trols and performed ex vivo osteoclast differentiation in the
presence of macrophage colony stimulating factor (MCSF) and
RANKL, with or without BRL (rosiglitazone) treatment. The induc-
tion of PGC1b during RANKL-mediated osteoclast differentiation
was markedly potentiated by BRL (Figure 1A). PGC1b induction
by BRL and RANKLwas PPARg dependent because it was abol-
ished in the PPARg/ cells differentiated from the bone marrow
of gf/fTie2cre mutants (Figure 1A). In contrast, a closely related
coactivator PGC1a was not induced by BRL or RANKL (data
not shown). The BRL induction of PGC1b preceded the BRL
induction of osteoclast marker genes (Figure 1B). Furthermore,
PGC1b protein induction by BRL and RANKL was confirmed
by western blot analysis (Figure 1C). These results showed that
ligand activation of PPARg strongly stimulates PGC1b expres-
sion during osteoclast differentiation.
To determine how PPARg and BRL induced PGC1b transcrip-
tion, we cloned a 1.8 Kb PGC1b promoter into a luciferase
reporter. Transient transfection analyses in several cell lines indi-
cated that BRL activation of PPARg had no significant effect on
the luciferase readout, suggesting that PPARg induced PGC1b
via indirect mechanisms. Of interest, we observed that BRL
stimulated PGC1b expression only during RANKL-induced oste-
oclast differentiation, but not in the macrophage precursors
before RANKL treatment (Figure 1A, time point 0 hr). This sug-
gested that there was a functional crosstalk between PPARg
and RANKL signaling and that BRL induction of the PGC1b pro-
moter required component(s) in the RANKL pathway. To identify
this component, we cotransfected various RANKL-activated
transcription factors, including c-fos, c-jun, NFAT-c1, and the
p65 subunit of NFkB, to determine which one(s) could induce
the PGC1b promoter. RANKL treatment of the cells transfected
with PGC1b-luc alone indeed activated the PGC1b promoter
by 1.4-fold. However, this induction was largely conferred by
c-jun, which robustly activated the PGC1b promoter by 7-fold,L and further elevated by BRL in theWT, but not PGC1b/ bone marrow differ-
y c-jun. HEK293 cells were cotransfected with a PGC1b-luc reporter and each
4 hr after transfection (RANKL, right). The same amount of total DNAwas trans-
he p values were calculated by comparing each condition to the vector trans-
egions, together with the AP-1 consensus.
-B promoter regions in bonemarrow differentiation cultures with or without BRL
tly inhibited by b-catenin. An expression vector encoding a constitutive active
b-catenin protein level was downregulated by RANKL and further diminished
hages were differentiated from the bone marrow of b-cateninflox/flox mice retro-
as measured by RT-QPCR.
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Figure 2. PGC1b Is Required For Rosiglitazone Stimulation of Osteoclast Differentiation
Bone marrow cells were isolated from PGC1bflox/flox; Tie2cre+/ (1b+cre) mutants or PGC1bflox/flox (1b-cre) controls and were differentiated ex vivo with RANKL
and MCSF in the presence or absence of BRL treatment.
(A) Representative images of the TRAP-stained osteoclast differentiation culture. Mature osteoclasts were identified as multinucleated TRAP+ cells. Scale bar,
25 mm.
(B) BRL induction of osteoclast marker genes was impaired during osteoclast differentiation from PGC1b/ bone marrow isolated from 1b+cre mutants.
R, RANKL; V, vehicle; B, BRL.
(C) BRL induction of ERRa and PGC1b, as well as their downstream targets of mitochondrial genes, was abolished during osteoclast differentiation from the
PGC1b/ bone marrow. Truncated PGC1b transcripts were detected using primers specific for sequences in exon 8 (Sonoda et al., 2007b). The p values
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PGC1b Is Required for TZD-Induced Bone Losswhereas the other factors tested had no significant effect (Fig-
ure 1D). Moreover, c-jun induced PGC1b promoter in a dose-
dependent manner because the luciferase output was reduced
by 56% in cells transfected with half the amount of c-jun. In addi-
tion, c-fos exerted neither activity nor interference because c-fos
had no effect on either the basal- or the c-jun-induced PGC1b
promoter expression, suggesting that c-jun functioned as homo-
dimers (Figure 1D). Two conserved AP-1 sites were identified in
the PGC1b promoter (Figure 1E). Chromatin immunoprecipita-
tion (ChIP) assay confirmed c-jun binding to these sites at the
endogenous mouse PGC1b promoter in bone marrow-derived
osteoclast precursors upon BRL and RANKL treatment, which
was associated with increased histone H3 acetylation, indicating
activation of PGC1b transcription (Figure 1F).
Surprisingly, cotransfection of a constitutively active b-catenin
mutant repressed both the basal expression and the c-jun induc-
tion of the PGC1b promoter by 56% and 72%, respectively
(Figure 1G). b-catenin is the downstream effector in the canon-
ical Wnt-signaling pathway and is regulated by protein degrada-
tion. Western blot analysis revealed that the b-catenin protein
level was reduced upon RANKL treatment, which was further
diminished by BRL in bone marrow-derived osteoclast precur-
sors (Figure 1H). Furthermore, b-catenin deletion or c-jun
overexpression is sufficient to induce PGC1b expression in
bone marrow-derived macrophages (Figure 1I). Together, these
results demonstrated that BRL activation of PPARg indirectly
induced PGC1b expression by downregulating b-catenin protein
level, thus derepressing c-jun, which directly activates the
PGC1b promoter.PGC1b Is Required for Rosiglitazone Stimulation
of Osteoclast Differentiation Ex Vivo
To determine the functional significance of the PPARg induction
of PGC1b, we examined whether PGC1b deletion affected
PPARg stimulation of osteoclastogenesis (Wan et al., 2007a).
We generated conditional PGC1b KO mice by crossing PGC1b
flox mice (Sonoda et al., 2007b) (1bf/f, see Figure S1 available
online) with Tie2cre transgenic mice (Constien et al., 2001;
Wan et al., 2007a). Our previous studies showed that Tie2cre
deletes flox alleles in all hematopoietic lineages, but not in mes-
enchymal lineages; thus, in osteoclasts, but not in osteoblasts
in bone (Wan et al., 2007a; Wan et al., 2007b). Bone marrow
cells were isolated from 1bf/fTie2cre mutants (1b+cre) or 1bf/f
littermate controls (1b-cre) and were differentiated ex vivo in
the presence of MCSF and RANKL, with or without BRL treat-
ment. The result demonstrated that PGC1b deletion severely
impaired the pro-osteoclastogenic effect of BRL. In the control
differentiation culture, BRL robustly stimulated the formation
of multinucleated TRAP+ (tartrate-resistant acid phosphatase)
mature osteoclasts, whereas this effect was abolished in the
1b+cre mutant culture (Figure 2A). Furthermore, PGC1b deletion
resulted in a markedly reduced ability of BRL to potentiate thedesignated as * were calculated by comparing 1bcre controls and 1b+cre mut
calculated by comparing +R/B and +R/V treatment conditions in the 1b-cre cells
(D) Alignment of mouse, rat, and human ERRa promoter PPRE region, together
(E) ChIP analysis of PPARg and PGC1b binding to the endogenous mouse ERRa
BRL and RANKL treatment; n = 3.
Error bars in (B), (C), and (E) represent means ± SD.
Cexpression of RANKL-induced transcription factors (c-fos and
NFATc1) and osteoclast function genes (TRAP, CAR2, andCalcr)
(Figure 2B). This indicated that PGC1b was required for BRL
stimulation of osteoclast differentiation, possibly as a coactivator
for either PPARg or other transcription factors in the specific
context of osteoclastogenesis.
PGC1b Coordinates with ERRa to Activate
Mitochondrial Function in Osteoclasts
Previous studies have shown that PGC1b functions as a
ligand-independent coactivator (or protein ligand) for estrogen
receptor-related receptor a (ERRa) to induce the expression
of medium-chain acyl-CoA dehydrogenase (MCAD), a pivotal
enzyme in mitochondrial fatty acid b-oxidation (FAO) (Kamei
et al., 2003). PGC1b activation of ERRa also induces other mito-
chondrial target genes involved in the tricarboxylic acid (TCA)
cycle and oxidative phosphorylation (OXPHOS), such as Ndg2
(Nur77 downstream gene 2), Aco2 (aconitase 2), IDH3a (isoci-
trate dehydrogenase 3), and ATP5b (ATP synthase 5b) (Sonoda
et al., 2007a). In light of the role of PGC1b in mitochondrial
biogenesis during osteoclast activation (Ishii et al., 2009), we
examined whether BRL could induce these ERRa/PGC1b target
genes. As shown in Figure 2C, BRL in conjunction with RANKL,
but not BRL or RANKL alone, increased the expression of ERRa,
thus resulting in the significant induction of its target genes,
including Ndg2, Aco2, IDH3a, ATP5b, MCAD, VLCAD, and
SCAD. Strikingly, BRL induction of these genes was completely
abolished in PGC1b/ differentiation culture, demonstrating
that it was PGC1b dependent. The fact that most of these genes
were only induced when ERRa was increased suggested that
they were ERRa targets. Furthermore, we identified a conserved
PPAR response element (PPRE) in the ERRa promoter (Fig-
ure 2D). ChIP assay demonstrated that both PPARg and PGC1b
were associated with this PPRE during BRL- and RANKL-
induced osteoclast differentiation (Figure 2E), suggesting that
ERRa is a direct PPARg target gene in the specific context of
osteoclastogenesis. Together, these results showed that BRL
activation of PPARg induced the expression of both PGC1b
and ERRa, which coordinately upregulated mitochondrial genes
during osteoclastogenesis.
ERRa Deletion Causes Osteoclast Defects
and Decreased Bone Resorption
To determine the role of ERRa in osteoclast differentiation
ex vivo, we compared the osteoclastogenic potential of the bone
marrow cells isolated from ERRa KO mice or ERRa heterozy-
gous (Het) control mice (Luo et al., 2003). ERRa deletion severely
compromised RANKL induction of several key osteoclast genes;
more strikingly, it blunted their stimulation by BRL (Figure 3A).
In addition, ERRa deletion also completely abolished the BRL
induction of the aforementioned mitochondrial genes, further
demonstrating that they were ERRa/PGC1b targets duringants under the same treatment conditions; the p values designated as + were
; n = 3.
with known PPREs for ap2, PEPCK, ACS, and DR-1 consensus.
promoter PPRE region in bone marrow differentiation cultures with or without
ell Metabolism 11, 503–516, June 9, 2010 ª2010 Elsevier Inc. 507
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(A and B) Bonemarrow cells were isolated from ERRaKOmice or ERRaHet controls and differentiated ex vivo with RANKL andMCSF in the presence or absence
of BRL treatment. RANKL-mediated and BRL-stimulated induction of osteoclast markers (A), as well as BRL induction of mitochondrial genes (B), were severely
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PGC1b Is Required for TZD-Induced Bone Lossosteoclastogenesis (Figure 3B). Consequently, the RANKL-
mediated and BRL-stimulated formation of mature osteoclasts
was impaired in the ERRa KO differentiation culture (Figure 3C).
These data suggested that ERRa deletion caused osteoclast
defects.
Consistently, the ERRa KO mice exhibited osteopetrosis
and extramedullary hematopoiesis in the spleen similar to the
gf/fTie2cre mice (Wan et al., 2007a). Bone marrow cell number
was decreased by 41% in ERRaKOs compared to ERRaHet
controls (Figure 3D, left), which was compensated by a 46%
increase in spleen cell numbers (Figure 3D, right). MicroCT anal-
ysis of the trabecular bone in the proximal tibia (Figure 3E)
revealed that the ERRa KO mice displayed higher bone volume.
Quantification of bone structure and architecture demonstrated
that the trabecular bone volume/tissue volume ratio (BV/TV) was
increased by 102% in ERRaKOs compared to ERRaHet con-
trols, accompanied by 79% greater bone surface (BS), 106%
greater trabecular number (Tb.N), 55% less trabecular separa-
tion (Tb.Sp), 3.3-fold greater connectivity density (Conn.D), and
28% less structure model index (SMI) (Figure 3F). This observa-
tion was confirmed by the statistically significant increases in
both the trabecular apparent density and the BV/TV of the entire
tibia, although the BV/TV of the cortical bone was not signifi-
cantly altered (Figure S2).
To determine whether the bone defects in ERRa KO mice
resulted from decreased bone resorption and/or increased bone
formation, we measured urinary CTX-1 (C-terminal telopeptides
of type-1 collagen) and serum osteocalcin levels, respectively.
CTX-1 was significantly reduced (39%, Figure 3G), whereas
osteocalcin was elevated (+18%) though statistically nonsignifi-
cant (Figure 3H). Consistently, histomorphometric analysis of
femoral metaphyses showed that ERRa KO mice exhibited
significantly less osteoclast surface (Oc.S/BS, 39%) and oste-
oclast number (Oc.N./B.Ar, 49%) (Figures 3I and 3J); in con-
trast, they had greater osteoblast surface and number (Fig-
ure S3). Moreover, BRL-induced bone resorption and bone
loss were severely diminished in ERRa KO mice (Figure S4).
Together, these results demonstrated that the osteopetrosis-
like phenotype in the ERRa KOs was mainly caused by
decreased bone resorption but also contributed to by increased
bone formation, leading to the uncoupling of bone remodeling
and a net gain of bone. Importantly, these results have identified
a previously unrecognized role for ERRa as a critical regulator of(C) Representative images of the TRAP-stained osteoclast differentiation cultur
Scale bar, 25 mm.
(D) ERRa KO mice exhibited extramedullary hematopoiesis in the spleen, evidenc
compared to littermate ERRaHet controls; n = 4.
(E and F) ERRa KOmice displayed increased bone mass. Tibiae from ERRaKOs o
and analyzed by mCT35.
(E) Representative images of the trabecular bone of the tibial metaphysis (top; sc
(F) Quantification of trabecular bone volume and architecture. BV/TV, bone volum
BS, bone surface; Conn.D., connectivity density; SMI, structure model index.
(G) Urinary concentration of a bone resorptionmarker CTX-1 (normalized to urinar
(H) Serum concentration of a bone formation marker osteocalcin was increased
(I and J) Histomorphometric analysis showed decreased osteoclasts in the ERRa
(I) Representative images of TRAP-stained femoral sections from ERRaKO or litte
(purple) cells. Scale bar, 100 mm.
(J) Quantification of osteoclast surface (Oc.S/BS) and osteoclast number (Oc.N/
Error bars in (A), (B), (D), (F), (G), (H), and (J) represent means ± SD.
Costeoclastogenesis and have provided in vivo evidence for ERRa
as a key PGC1b target to promote bone resorption.
PGC1b Functions as a PPARg Coactivator to Promote
Osteoclast Differentiation
Next, we examined whether PGC1b also functioned as a tran-
scriptional coactivator for PPARg. First, we tested the effect of
PGC1b on PPARg activation of a consensus PPAR response
element (PPRE)-driven luciferase reporter in a transient transfec-
tion assay of the RAW 264.7 macrophage cell line. Cotransfec-
tion of PGC1b with PPARg and RXRa potentiated the BRL acti-
vation of PPRE, resulting in a 12.5-fold induction, compared to
a 5.2-fold induction for the receptors alone and a 2.6-fold induc-
tion for PGC1b alone (Figure 4A). Second, we tested whether
PGC1b functioned through the PPARg ligand-binding domain
(LBD) by examining its ability to stimulate the BRL activation
of a Gal4DBD-PPARgLBD fusion protein (Forman et al., 1995).
To determine whether PGC1b could increase the potency of
BRL to activate PPARg LBD, we conducted a dose curve of
BRL treatment (0.01, 0.1, and 1 mM). To investigate whether
the coactivation was PGC1b dose dependent, PGC1b expres-
sion plasmid was transfected at a low (20 ng) or high (100 ng)
amount. The results demonstrated that PGC1b indeed acted
through PPARg LBD and sensitized PPARg LBD to ligand activa-
tion at a lower BRL concentration in a PGC1b dose-dependent
manner (Figure 4B). Third, PGC1b enhanced the PPRE activation
by a constitutively active VP16-PPARg fusion protein (Saez et al.,
2004), but not anAF2domain-deletedPPARgmutant (Figure 4C),
further confirming that PPARg LBD was required for PGC1b
coactivation.
In our previous study, we identified c-fos, a key regulator of
osteoclast differentiation (Grigoriadis et al., 1994), as a direct
PPARg target (Wan et al., 2007a). Thus, we tested whether
PGC1b could enhance the ability for PPARg to induce the
c-fos promoter in RAW 264.7 cells upon BRL stimulation. The
results showed that PGC1b potentiated the BRL induction of
c-fos by 2.1-fold (Figure 4D). Furthermore, ChIP assays demon-
strated that PGC1b was indeed recruited to the two previously
identified PPREs (Wan et al., 2007a) in the endogenous c-fos
promoter upon BRL stimulation of the bone marrow-derived
osteoclast precursors, resulting in increased histone H3 acetyla-
tion and thus c-fos transcriptional activation (Figure 4E).
Together, these data provided strong evidence that PGC1be. Mature osteoclasts were identified as multinucleated TRAP+ (purple) cells.
ed by reduced bone marrow cell numbers and increased splenocyte numbers
r littermate ERRaHet controls (10- to 12-month-old male; n = 4) were scanned
ale bar, 10 mm) and the entire proximal tibia (bottom; scale bar, 1 mm).
e/tissue volume ratio; Tb.N, trabecular number; Tb.Sp, trabecular separation;
y creatinine concentration) was significantly decreased in ERRa KOmice; n = 4.
in ERRa KO mice, but the difference was statistically nonsignificant; n = 4.
KO mice; n = 4.
rmate ERRaHet controls. Osteoclasts were identified as multinucleated TRAP+
B.Ar); B.Ar, bone area.
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Figure 4. PGC1b Functions as a PPARg Transcriptional Coactivator
(A) PGC1b potentiated the BRL activation of the consensus PPAR response element (PPRE). Expression plasmids for PPARg (g), RXRa (a), and PGC1b (1b) or
vector control (vec) were transfected into the RAW 264.7 macrophage cell line, along with the reporter PPREx3-TK-luc.
(B) PGC1b potentiated the BRL activation of a Gal4DBD-PPARgLBD fusion protein and sensitized PPARg LBD to ligand activation at lower BRL concentration in
a PGC1b dose-dependent manner. Expression plasmids for Gal4DBD-PPARgLBD (gLBD) and/or PGC1b (1b) were transfected as indicated, along with the Gal4
reporter UASGx4-TK-luc. PGC1b were transfected at 20 ng (low 1b) or 100 ng (hi 1b). BRL treatment was at the indicated concentration.
(C) PGC1b increased the PPRE activation by a constitutively active VP16-PPARg fusion protein (VP16 g), but not an AF2 domain deleted PPARgmutant (g-dAF2).
(D) PGC1b enhanced the ability for PPARg to induce the c-fos promoter upon BRL stimulation.
(E) ChIP analysis of PGC1b recruitment to the endogenous mouse cfos-A and cfos-B PPRE regions in bone marrow differentiation cultures with or without BRL
and RANKL treatment. The p values were calculated by comparing BRL and vehicle treatment; n = 3.
Error bars in (A)–(E) represent means ± SD.
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BRL stimulation of osteoclast differentiation.
Osteoclastic PGC1b Is Required
for Rosiglitazone-Induced Bone Loss In Vivo
To further delineate the specific requirement for osteoclastic
PGC1b in rosiglitazone-induced bone resorption and bone loss
in vivo, we treated 8-month-old 1bf/fTie2cre mutants (1b+cre)510 Cell Metabolism 11, 503–516, June 9, 2010 ª2010 Elsevier Inc.and 1bf/f littermate controls (1b-cre) with BRL (10 mg/kg/day)
or vehicle daily by oral gavage for 8 weeks. MicroCT imaging
of the proximal tibiae revealed that the BRL-mediated reduction
in trabecular bone in control mice was completely abolished in
the 1b+cre mutants (Figures 5A and 5B). Quantification of
bone parameters showed that BRL significantly decreased the
BV/TV in the controls (31%), whereas a statistically nonsignifi-
cant increase (+2%) was found in the mutants. Consistently, in
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Figure 5. Osteoclastic PGC1b Is Required for Rosiglitazone-Induced Bone Loss In Vivo
PGC1bf/fTie2cre mutant mice (1b+cre) and PGC1bf/f littermate control mice (1b-cre) (8-month-old male) were treated with BRL at 10 mg/kg/day or vehicle daily
by oral gavage for 8 weeks; n = 4 or 5 in each group.
(A–C) MicroCT imaging and analysis of the tibiae.
(A) Representative images of the trabecular bone of the tibial metaphysis. Scale bar, 10 mm.
(B) Representative images of the entire proximal tibia. Scale bar, 1 mm.
(C) Quantification of trabecular bone volume and architecture. BV/TV, bone volume/tissue volume ratio; BS, bone surface; BS/BV, bone surface/bone volume
ratio; Tb.N, trabecular number; Tb.Sp, trabecular separation; SMI, structure model index.
(D and E) Histomorphometric analysis showed that BRL increased osteoclast surface and number in control mice (1b-cre), but not in mutants (1b+cre).
(D) Representative images of TRAP-stained femoral sections. Osteoclasts were identified as multinucleated TRAP+ (purple) cells. Scale bar, 100 mm.
(E) Quantification of osteoclast surface (Oc.S/BS) and osteoclast number (Oc.N/B.Ar). B.Ar, bone area.
(F) Serum concentration of a bone formation marker osteocalcin.
(G) Urinary concentration of a bone resorption marker CTX-1 (normalized to urinary creatinine concentration).
Bars in (C), (E), (F), and (G) represent means ± SD.
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Figure 6. A Simplified Model for How PGC1b Mediates PPARg Activation of Osteoclast Differentiation and Bone Resorption
Rosiglitazone-activated PPARg, in concert with RANKL signaling, indirectly induces PGC1b expression by downregulating b-catenin protein, thus stimulating
both basal- and c-jun-induced PGC1b transcription. PGC1b, in turn, forms a positive feedback loop by functioning as a PPARg coactivator to induce PPARg
target genes such as c-fos, thereby stimulating osteoclast differentiation. Complementarily, rosiglitazone-activated PPARg also induces ERRa expression during
osteoclast differentiation. PGC1b acts as an ERRa coactivator (or protein ligand) to inducemitochondrial genes involved in fatty acid b-oxidation (FAO) and oxida-
tive phosphorylation (OXPHOS), thereby promoting mitochondrial biogenesis and activation. By coordinating two distinct transcriptional programs enhancing
osteoclast differentiation and mitochondrial activation, PGC1b mediates PPARg stimulation of osteoclastogenesis and rosiglitazone-induced bone loss.
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along with an 18% greater bone surface/bone volume ratio
(BS/BV, data not shown), as well as a 19% less trabecular
number (Tb.N) along with a 28% greater trabecular separation
(Tb.Sp), all indicating a lesser trabecular bone apparent density.
Moreover, BRL also led to skeletal fragility in the control mice,
evidenced by a 23% greater SMI, a parameter that quantifies
the characteristic form of a three-dimensional structure in terms
of the relative amount of plates (SMI = 0, strong bone) and rods
(SMI = 3, fragile bone) independent of the physical dimensions
(Hildebrand and Ru¨egsegger, 1997). Strikingly, all of these
parameters were unaltered by BRL in the 1b+cre mutants (Fig-
ure 5C). Of interest, no statistically significant differences were
found in any structural measurements between the mutants
and controls under vehicle-treated conditions (Figure 5C).
Histomorphometric analysis of femoral metaphyses revealed
that BRL significantly increased both osteoclast surface (Oc.S/
BS, +76%) and osteoclast number (Oc.N/B.Ar, +69%) in the
controls, but this induction was abolished in the 1b+cre mutants
(Figures 5D and 5E). In contrast, osteoblast surface and number
were not significantly altered (Figure S5). Consistently, although
serum osteocalcin was nonsignificantly decreased in both con-
trols (25%) and mutants (13%) by BRL (Figure 5F), urinary
CTX-1 was significantly increased in the controls (+45%) but
decreased in the mutants (22%) by BRL (Figure 5G). This dem-
onstrated that, in the control mice, bone resorption and bone
formation were uncoupled by BRL, thus leading to a net loss
of bone. In contrast, in the 1b+cre mutants, loss of PGC1b in
hematopoietic progenitors rendered them refractory to the
osteoclast-stimulating effect of BRL; therefore, the coupling of
bone resorption and bone formation was maintained, and bone
loss was prevented. Intriguingly, there was a reduction in both512 Cell Metabolism 11, 503–516, June 9, 2010 ª2010 Elsevier Inc.CTX-1 (45%) and osteocalcin (11%) in the vehicle-treated
1b+cre mutants compared to the 1b-cre controls (Figure 5F–5G)
despite the unaltered BV/TV (Figure 5C). This indicated that oste-
oclastic PGC1b deletion indeed suppressed basal bone resorp-
tion, yet this defect was largely compensated by a simultaneous
reduction in bone formation, presumably through the coupling
mechanism, thus preserving skeletal homeostasis. Collectively,
these results provided compelling evidence that PGC1b deletion
in the osteoclast lineage confers a complete resistance to BRL-
induced bone resorption and bone loss; therefore, PGC1b is an
essential mediator of PPARg activation of osteoclastogenesis
in vivo.
DISCUSSION
This study has elucidated the molecular mechanisms for
how PPARg and rosiglitazone stimulate osteoclastogenesis by
orchestrating the downstream targets PGC1b and ERRa. Using
several mouse models with genetically altered PPARg, PGC1b,
or ERRa, we have provided in vitro, ex vivo, and in vivo evidence
that PGC1b is required for the pro-osteoclastogenic and
bone resorption-enhancing effects of PPARg and rosiglitazone.
PPARg and PGC1b form a positive feedback loop. On one
hand, PPARg activation indirectly induces PGC1b expression
by downregulating b-catenin protein level, thus derepressing
c-jun, which directly activates the PGC1b promoter; on the other
hand, PGC1b functions as a PPARg coactivator to stimulate the
transcription of its target genes such as c-fos, thus promoting
osteoclast differentiation (Figure 6). Moreover, PGC1b also coor-
dinates with ERRa to induce genes required for mitochondrial
biogenesis and fatty acid oxidation, thereby activating osteo-
clast function (Figure 6). Strikingly, targeted deletion of PGC1b
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tazone-induced bone loss. Together, these findings demon-
strate that PGC1b mediates the pro-osteoclastogenic function
of PPARg by targeting both PPARg itself and ERRa, thus acti-
vating two distinct transcriptional programs (Figure 6).
As acid- and proteinase-secreting polykaryons, osteoclasts
are in a state of high-energy demand and possess abundant
mitochondria (Brown and Breton, 1996; Ishii et al., 2009).
A recent study revealed that PGC1b coordinates with iron uptake
to orchestratemitochondrial biogenesis during osteoclast devel-
opment (Ishii et al., 2009). However, the molecular mechanism
by which PGC1b exerts this function was unknown, and how
PGC1b interacts with the osteoclast differentiation program
provoked by RANKL and PPARg remained underexplored. Our
present study demonstrates that PGC1b functions as a transcrip-
tional coactivator for both PPARg and ERRa to induce the
expression of c-fos and mitochondrial genes, thus linking osteo-
clast differentiation with osteoclast activation.
Osteoclast differentiation and mitochondrial activation cross-
talk with each other. For example, reactive oxygen species gen-
erated by the mitochondria can stimulate osteoclast differentia-
tion by inducing Ca2+ oscillations and NFATc1 activation (Kim
et al., 2010); conversely, transcription factors activated during
osteoclast differentiation induce target gene expression to pro-
mote osteoclast function and mitochondrial biogenesis (Ishii
et al., 2009; Novack and Teitelbaum, 2008). Our proposedmodel
(Figure 6) illustrates that the direct downstream targets of ERRa
are mitochondrial genes, but ERRa also indirectly regulates
osteoclast differentiation. Moreover, we have previously shown
that PPARg deletion impairs osteoclast differentiation, demon-
strating that basal PPARg activity, potentially induced by endog-
enous PPARg ligands, is required for efficient osteoclastogene-
sis (Wan et al., 2007a). Therefore, both PGC1b and ERRa
deletions compromise the basal PPARg activity, resulting in
fewer osteoclasts induced by RANKL ex vivo and lower bone
resorption in vivo.
A recent report suggested that ERRa inhibits osteoblastogen-
esis and enhances adipogenesis (Delhon et al., 2009). Our
present study reveals a previously unrecognized role for ERRa
in promoting osteoclastogenesis by inducing the expression
of mitochondrial genes via a PGC1b-dependent mechanism.
Furthermore, a polymorphic autoregulatory hormone response
element on the human ERRa promoter (Laganie`re et al., 2004)
has been found to be associated with bone mineral density
(Laflamme et al., 2005). Together, these findings not only identify
ERRa as a critical regulator of skeletal and mineral homeostasis,
but also highlight a functional link between PPARg and ERRa
pathways, converging at the transcriptional coactivator PGC1b.
Rosiglitazone induces bone loss by stimulating bone resorp-
tion and inhibiting bone formation, both of which are required
for the uncoupling of bone remodeling. However, the rela-
tive effect of rosiglitazone on osteoclast and osteoblast is age
dependent. In old mice, rosiglitazone increases bone resorption
while sustaining bone formation; in contrast, in young mice,
rosiglitazone decreases bone formation while sustaining bone
resorption (Lazarenko et al., 2007). In our study, 8 week rosiglita-
zone treatment significantly increased osteoclast number
(Figure 5E) and bone resorption (Figure 5G) in 8- to 10-month-
old mice. If the coupling of bone remodeling was intact, thereCshould have been an increase in osteoblast number and bone
formation as well, yet we observed a reduction in the osteocalcin
bone formation marker (Figure 5F) and unaltered osteoblast
number (Figure S5). Therefore, relatively speaking, rosiglitazone
indeed suppressed osteoblast number and bone formation in
our study. This is consistent with previous findings that ligand
activation of PPARg inhibits osteoblastogenesis from the mes-
enchymal stem cells by favoring adipogenesis (Akune et al.,
2004; Barak et al., 1999; Cock et al., 2004; Kubota et al., 1999;
Rosen et al., 1999); on the other hand, repression of PPARg by
canonical or noncanonical Wnt signaling enhances osteoblasto-
genesis by reducing adipogenesis (Kang et al., 2007; Takada
et al., 2007). Our study identifies osteoclastic PGC1b as an
essential mediator of the bone resorption-enhancing effect
by rosiglitazone, which acts in concert with the bone forma-
tion-suppressing effect by rosiglitazone to induce uncoupling
and bone loss.
In summary, this study demonstrates that rosiglitazone stimu-
lates osteoclastogenesis and bone resorption via a transcrip-
tional network comprised of PPARg, PGC1b, and ERRa. Pro-
vocatively, rosiglitazone-mediated activation of adipogenesis
and suppression of osteoblastogenesis has been shown to be
partially attributed to the coactivator SRC-2 (Mo¨dder et al.,
2009). Therefore, PPARg recruits distinct transcriptional coacti-
vators in hematopoietic and mesenchymal lineages to confer
differential regulation of osteoclast and adipocyte development.
Importantly, this mechanistic understanding of cell type-specific
gene regulation by PPARg will facilitate the design of improved
diabetic drugs, such as selective PPARgmodulators (SPPARMs)
that retain the insulin-sensitizing benefits but dampen the detri-
mental bone loss effects.
EXPERIMENTAL PROCEDURES
Mice
PPARgflox/flox; Tie2cre+/mice (Wan et al., 2007a), PGC1bflox/flox mice (Sonoda
et al., 2007b), ERRa KO mice (Luo et al., 2003), and b-cateninflox/flox mice
(Brault et al., 2001) have been described. To specifically delete PGC1b in
hematopoietic lineages and endothelial cells, we bred PGC1bflox/flox (1bf/f)
mice (backcrossed toC57BL/6J for at least six generations) with Tie2cre trans-
genic mice (Kisanuki et al., 2001) to generate 1bf/fTie2cre+/ mice and 1bf/f
littermate controls. All protocols for mouse experiments were approved by
the Institutional Animal Care and Use Committee of University of Texas South-
western Medical Center.
Bone Analyses
To evaluate bone volume and architecture by micro-computed tomography
(microCT), mouse tibiae were fixed in 70% ethanol and scanned using
a Scanco mCT-35 instrument (SCANCO Medical) at several resolutions for
both overall tibial assessment (14micron resolution) and the structural analysis
of trabecular and cortical bone (7 micron resolution). Trabecular bone param-
eters were calculated using the Scanco software to analyze the bone scans
from the trabecular region directly distal to the proximal tibial growth plate.
Histomorphometric analyses were conducted using the BIOQUANT Image
Analysis software (Bioquant). TRAP staining of osteoclasts was performed
using the Leukocyte Acid Phosphatase staining kit (Sigma). ALP staining of
osteoblasts was performed using the Alkaline Phosphatase staining kit
(Sigma). As a bone resorption marker, urinary C-terminal telopeptide frag-
ments of the type I collagen (CTX-1) were measured with the RatLaps EIA kit
(Immunodiagnostic Systems) and normalized by urinary creatinine measured
by the Infinity Creatinine Reagent (Thermo Scientific). As a bone formation
marker, serum osteocalcin was measured with the mouse osteocalcin EIA
kit (Biomedical Technologies, Inc.).ell Metabolism 11, 503–516, June 9, 2010 ª2010 Elsevier Inc. 513
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Osteoclasts were differentiated from mouse bone marrow cells as described
(Kawano et al., 2003; Wan et al., 2007a). In brief, cells were differentiated
with 40 ng/ml of M-CSF (R&D Systems) in a-MEM containing 10% FBS for
3 days and then with 40 ng/ml of MCSF and 100 ng/ml of RANKL (R&D
Systems) for 3 days, in the presence or absence of BRL (1 mM, unless other-
wise stated). Retroviral gene transduction was performed as previously
described (Wan et al., 2007a). Mature osteoclasts were identified as multinu-
cleated (>3 nuclei) TRAP+ cells. Osteoclast differentiation was quantified by
the RNA expression of RANKL-induced transcription factors and osteoclast
function genes using RT-QPCR analysis.
Gene Expression Analyses
RNA was reverse transcribed into cDNA using an ABI High Capacity cDNA RT
kit and analyzed using real-time quantitative PCR (SYBR Green) in triplicate.
All RNA expression was normalized by L19. Antibodies used for western blots
were: PGC1b (Santa Cruz), b-catenin (BD Biosciences), and b-actin (Sigma).
Promoter Analyses
For transient transfection, a luciferase reporter was cotransfected into the
mouse macrophage cell line RAW264.7 cells or HEK293 cells with expression
plasmids for b-gal and factors to be tested using FuGENE HD reagent
(Roche). Vector alone served as a negative control. The next day, the cells
were treated with BRL or DMSO vehicle control overnight. Luciferase activity
was normalized by b-gal activity. All transfection experiments were performed
in triplicates and repeated at least three times. Luciferase reporters PPREx3-
TK-luc, UASGx4-TK-luc, and c-fos1.1kb-luc have been previously described
(Forman et al., 1995; Wan et al., 2007a). A 1.8 Kb genomic DNA fragment
upstream of the mouse PGC1b transcription start site was cloned into the
pGL3Basic vector to generate the PGC1b-luc reporter. Expression plasmids
for PPARg, RXRa, PGC1b, VP16-PPARg, and PPARg-dAF2 mutant were
previously described (Saez et al., 2004; Sonoda et al., 2007b; Wan et al.,
2007a). An expression plasmid for a constitutively active b-catenin mutant
was generously provided by Dr. Chi Zhang (Texas Scottish Rite Hospital for
Children). Expression plasmids for c-jun, c-fos, NFATc1, and p65 were
purchased from Open Biosystems. Promoter sequence alignment was per-
formed using Vector NTI Advanced 11 AlignX software (Invitrogen). ChIP
assays were performed using mouse bone marrow-derived osteoclast
precursors that were treated with BRL/RANKL/MCSF or MCSF alone for
3 days as previously described (Wan et al., 2007a). Antibodies used were:
c-jun (Cell Signaling), PGC1b (Santa Cruz), acetyl-Histone H3 (Upstate/Milli-
pore), PPARg (Santa Cruz), and IgG negative control (BD Biosciences).
ChIP output was quantified by real-time PCR in triplicates and normalized
by 10% input.
Statistical Analyses
All statistical analyses were performed with Student’s t test and represented
as mean ± standard deviation (SD). The p values were designated as:
*p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001; *****p < 0.0005; ******p <
0.0001; ns, nonsignificant (p > 0.05).SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and can be found with this
article online at doi:10.1016/j.cmet.2010.04.015.
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